Skip to main content

Day: December 15, 2025

Voltalia SA: Total number of shares and voting rights in the share capital as of October 31, 2025 

Total number of shares and voting rights in the share capital as of October 31, 2025 (Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) Date  Total number of shares in the capital   Number of theoretical voting rights  Number of exercisable voting rights 10/31/2025  131 318 716 223 413 961 223 021 890Next on the agenda: Q4 2025 turnover, January 28, 2026 (after market close)About Voltalia (www.voltalia.com)Voltalia is an international player in the renewable energy sector. The Group produces and sells electricity generated from wind, solar, hydraulic, biomass and storage facilities that it owns and operates. Voltalia has generating capacity in operation and under construction of more than 3.3 GW and a portfolio of projects under development...

Continue reading

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND POTENTIALLY OTHER CANCERSAB8939 is a promising drug candidate for refractory AML, especially for cases with poor prognoses such as complex karyotypes, MECOM rearrangements, and TP53 mutations AB8939 has dual action against both proliferating tumor cells (via tubulin disruption) and quiescent, resistant stem cells (via ALDH inhibition) making it a unique therapeutic agent Based on these findings, AB8939 is being evaluated in a Phase I/II clinical trial for relapsed or refractory AMLParis, December 15, 2025, 6.30pm CET AB Science SA (Euronext – FR0010557264 – AB) today announced the publication of...

Continue reading

Evolve Royalties Ltd. Announces Completion of its Business Combination and Listing on the CSE

Evolve to commence trading on the CSE on December 17, 2025 under the ticker symbol “EVR” Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) — Evolve Royalties Ltd. (CSE: EVR) (“Evolve” or the “Company”) (formerly Voyageur Minerals Explorers Corp.) is pleased to announce that it has completed its previously-announced business combination (the “Business Combination”) with Evolve Strategic Element Royalties Ltd. and its listing on the Canadian Securities Exchange (“CSE”). Evolve’s common shares (the “Evolve Shares”) are expected to commence trading on the CSE on December 17, 2025 under the symbol “EVR”. The Company’s listing statement is available on its...

Continue reading

Advini and Cordier by InVivo announce their entry into exclusive negotiations to strengthen their position in the French wine industry

Advini and Cordier by InVivo Announce Their Entry into Exclusive Negotiations to Strengthen Their Position in the French Wine Industry Advini Group and Cordier by InVivo announce entry into exclusive negotiations to merge certain activities This merger, sought by both groups, fits perfectly into a strategy of brand, product range, and sales network complementarity. It would allow Advini to strengthen its position in the Bordeaux region with the Cordier brand and enter the sparkling wine market with Café de Paris. Additionally, Advini’s export activities would be enhanced through Cordier’s distribution subsidiaries and presence, in the Netherlands, Belgium, the United States, Canada, South Africa, and Japan. AdVini would benefit from a wider and more diversified portfolio of prestigious brands, as well as a stronger distribution...

Continue reading

Berry Stockholders Approve Combination with CRC

DALLAS, Dec. 15, 2025 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry”) today announced that, at its Special Meeting of Stockholders held earlier today, Berry stockholders voted to approve its combination with California Resources Corporation (“CRC”) (NYSE: CRC). As previously announced, under the terms of the merger agreement, Berry stockholders will receive a fixed exchange ratio of 0.0718 shares of CRC common stock for each share of Berry common stock. According to preliminary results, Berry stockholders approved the transaction with approximately 73% of the total shares outstanding and approximately 98% of the shares voted in support of the combination. The final voting results of Berry’s Special Meeting will be reported in a Form 8-K to be filed with the U.S. Securities and Exchange Commission (the “SEC”). The...

Continue reading

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program...

Continue reading

Society Pass Incorporated (Nasdaq: SOPA) Rolls Out M&A Strategy to Capture Potential Significant Valuation Opportunities in Global Landscape of Privately Held Companies

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — As part of its ongoing corporate transformation, Society Pass Incorporated (Nasdaq: SOPA) (the “Company”), Southeast Asia’s (SEA) next generation e-commerce ecosystem, today announces the roll out of a comprehensive mergers and acquisition (“M&A”) strategy to capture potential significant valuation arbitrage acquisition opportunities across privately-held companies located in SEA, Europe and North America. The Company will be partnered up with selected regional and global private equity firms to assist it with deal flow and execution to cement its market leadership in the AI data centre, travel, digital advertising, and telecommunications sectors. Raynauld Liang, CEO of the Company, explains, “The Company’s success in listing (Nasdaq: NUTR) into a stand-alone public company is testament...

Continue reading

Baltic Horizon Fund publishes its NAV for November 2025

The net asset value (NAV) per unit of the Baltic Horizon Fund (the Fund) decreased to EUR 0.5446 at the end of November 2025 (0.6783 as of 31 October 2025). The month-end total net asset value of the Fund was EUR 78.2 million (EUR 97.4 million as of 31 October 2025). The EPRA NRV as of 30 November 2025 stood at EUR 0.5851 per unit. At the end of November 2025, new portfolio valuations were conducted by the independent real estate appraisers. As of 30 November 2025, the fair value of the Baltic Horizon Fund portfolio decreased to EUR 208.7 million (31 December 2024: 224.5 million excluding the disposed Meraki property). Compared to the previous valuations, the change in portfolio value was mainly driven by the changes in discount rates and exit yields, as well as changes in foreseeable occupancies and projected investments into tenant fit-outs....

Continue reading

SCOR’s Actuarial Awards reward outstanding research across six countries in 2025

Press release15 December 2025 – N° 19   SCOR’s Actuarial Awards reward outstanding research across six countries in 2025 Each year for almost 30 years, SCOR has rewarded the best research in the field of actuarial science with prizes in several countries. These prizes are designed to promote the development of actuarial science, to encourage research in this field, and to contribute to the improvement of risk knowledge and management. The SCOR Actuarial Awards are recognized in the insurance and reinsurance industries as a mark of excellence. The Actuarial Awards in France are supported by the SCOR Corporate Foundation for Science, chaired by Pierre-André Chiappori. The SCOR Actuarial Awards juries are composed of internationally recognized researchers and insurance, reinsurance and finance professionals. The winners are selected...

Continue reading

Cornish Metals Announces Update Regarding the Last Day of Trading on AIM in Relation to Its Proposed Re-Domicile

VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) — Cornish Metals Inc. (AIM/TSXV: CUSN) (“Cornish Metals”, “Cornish Canada” or the “Company”) a mineral exploration and development company focused on advancing its wholly owned and permitted South Crofty tin project in Cornwall, United Kingdom, provides a further update following the receipt of the final order from the Ontario Superior Court of Justice (the “Court Order“) approving the previously announced re-domicile of the Company (the “Arrangement“). The Arrangement will result in the transfer all of the issued and outstanding common shares of the Company (each a “Cornish Canada Share“) to Cornish Metals plc (“Cornish UK“) in exchange for the issue to the Company’s shareholders of new shares in Cornish UK (each...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.